Stoke Therapeutics Completes Enrollment of 162 Patients in EMPEROR Study
Stoke Therapeutics announced the completion of enrollment of 162 patients into the Phase 3 EMPEROR study of zorevunersen. Stoke plans to initiate a rolling New Drug Application, NDA, submission to the U.S. Food and Drug Administration, FDA, in the first quarter of 2027. A Phase 3 data readout is anticipated in the third quarter of 2027 to complete the rolling U.S. NDA submission in the second half of 2027.
